Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer

Table 3

Clinical trials with bevacizumab in first-line treatment.

Study	No. of patients	Design	Treatment	Primary end point	Results
Kabbinavar et al. [62]	104	Phase 2, randomized	FU/LV versus	TTP	5.2 versus 7.4 months	0.013
			Low dose bevacizumab + FU/LV; High dose bevacizumab + FU/LV	Best response rate	17% versus 32%	0.086
Kabbinavar et al. [63]	209	Phase 2, randomized	FU/LV + placebo versus FU/LV + bevacizumab	OS	12.9 versus 16.6 months; HR, 0.79	0.16
Hurwitz et al. [64]	813	Phase 3, double-blind, RCT	IFL + placebo versus IFL + bevacizumab	OS	15.6 versus 20.3 months; HR, 0.66	<0.001
NO 16966 [65]	1401	Phase 3, double-blind, RCT	CapeOx + placebo or CapOx + bevacizumab versus FOLFOX + placebo or FOLFOX + bevacizumab	PFS	HR, 0.83; 95% CI, 0.72–0.95	0.0023
Passardi et al. [69]	376	Phase 3, randomized	FOLFIRI or FOLFOX + bevacizumab versus FOLFIRI or FOLFOX	PFS	HR, 0.86; 95% CI, 0.70–1.07	0.182

No.: number; TTP: time to progression; RCT: randomized controlled trial; OS: overall survival; HR: hazard ratio; PFS: progression-free survival; CI: confidence interval.